Fig. 3 | Scientific Reports

Fig. 3

From: Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway

Fig. 3

Tafasitamab plus metronomic vinorelbine significantly inhibit phosphorylation of the Akt/mTOR signaling pathway. Luminex analysis of phospho GSK3α (A), GSK3β (B), mTOR (C), p70S6K (D), RPS6 (E) and TSC2 (F) in Toledo, OCI-LY3 and SU-DHL10 cells treated with tafasitamab (TAFA) alone or in concomitant combination with vinorelbine (VNR) and etoposide (ETO) for 24 h at their experimental cytotoxic IC50s. Results were reported as the percentage of the phosphorylated protein vs. 100% of phosphorylated proteins in IgG1-treated cells. Columns and bars, mean values ± S.E.M., respectively. *P < 0.05 vs. human IgG1 isotype controls; °P < 0.05 for TAFA vs. VNR + TAFA.

Back to article page